{
  "id": 10511675,
  "title": "Truist reiterates Buy on Inventiva stock ahead of phase 3 data",
  "url": "https://urgent.news/2026/09/28/truist-reiterates-buy-on-inventiva-stock-ahead-of-phase-3-data",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-28T18:54:50.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/truist-reiterates-buy-on-inventiva-stock-ahead-of-phase-3-data-93CH-4921016"
  },
  "original_language": "en",
  "account": "Truist Securities has maintained its Buy rating and $13.00 price target for Inventiva SA (NASDAQ:IVA) shares, ahead of the company's anticipated phase 3 data. The stock is currently trading at $3.53, marking a 44% decline over the past year, though the analyst target suggests significant upside potential. InvestingPro analysis indicates that the stock may be overvalued at its current price relative to its fair value. The firm highlights a substantial market opportunity with two drugs already approved, coupled with an unmet need in a heterogeneous Metabolic Acidosis and Hyperkalemia (MASH) population. Strong phase 2 data showcases an 18% placebo-adjusted fibrosis improvement at six months, with the potential for a deeper response at the 18-month endpoint. Key opinion leaders suggest that weight gain and edema side effects are manageable and could be outweighed by significant fibrosis and cardiometabolic improvements. Inventiva anticipates phase 3 NATiV3 data for lanifibranor in MASH during the fourth quarter of 2026. Should the trial prove successful, Truist envisions a new drug application filing in the first half of 2027 and a 2028 U.S. commercial launch. This reassessment of the stock aligns with Inventiva's recent earnings beat for the second quarter of 2026, where the company reported better-than-expected earnings and revenue. Despite positive financial results, investor attention remains focused on Inventiva's late-stage MASH drug program and the associated risks stemming from upcoming Phase III data.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}